Dexcom Inc


Market Cap$45.85B

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Dexcom IncDexcom Inc71.70%28%131.1

Earnings Call Q4 2023

February 8, 2024 - AI Summary

Dexcom reported strong financial results for the fourth quarter and fiscal year 2023, with total revenue growing by 27% on a reported basis and 26% on an organic basis.
The company added over 600,000 new customers in 2023, ending the year with approximately 2.3 million customers globally.
Dexcom's G7 CGM system has been well-received in the market, driving changes in prescribing patterns and attracting a larger cohort of clinicians to the ecosystem.

Exclusive for Stockcircle Pro members

Sign upSign Up

Target Price by Analysts

26.6% upsideDexcom Target Price DetailsTarget Price

Current Fair Value

73.9% downside

Overvalued by 73.9% based on the discounted cash flow analysis.

Share Statistics

Market cap$45.85 Billion
Enterprise Value$45.45 Billion
Dividend Yield$0.0 (0.0%)
Earnings per Share$1.5
Outstanding Shares397,683,837
Avg 30 Day Volume2,710,377


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio71.72
Price to Sales13.02
Price to Book Ratio23.44
Enterprise Value to Revenue11.95
Enterprise Value to EBIT69.55
Enterprise Value to Net Income71
Total Debt to Enterprise0.05
Debt to Equity1.11

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Dexcom Inc

CEO: Kevin Sayer